QPPV.COM KNOWLEDGE ASSESSMENT

Iberdomide (Zenbexus): CELMoD Development, Accelerated Approval and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Iberdomide (Zenbexus): CELMoD Development, Accelerated Approval and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which organisational arrangement best supports pharmacovigilance oversight of an accelerated-approval product with a REMS?

Keep trial safety, regulatory commitments and REMS information within their respective functions to preserve independence. Transfer ownership of all confirmatory-trial activities to the QPPV. Use spontaneous reports as the only information source after approval. Define interfaces so relevant trial findings, regulatory commitments and REMS experience reach pharmacovigilance for appropriate evaluation.

Question 2 of 10 A new malignant tumour is diagnosed during iberdomide treatment. Which initial classification approach is most appropriate?

Classify it as multiple-myeloma progression unless the patient has stopped iberdomide. Evaluate it as a potential second primary malignancy, distinct from progression of the treated myeloma. Exclude it from safety assessment because malignancy is expected in this population. Assume it is an adverse reaction because second primary malignancies are an identified concern.

Question 3 of 10 A pregnancy exposure is reported in a patient receiving iberdomide. Which follow-up approach is most appropriate?

Collect exposure dates, dose and cycle, pregnancy timing, relevant contraception information, outcome and any congenital or developmental findings. Close the case once the exposure is confirmed because the REMS has already addressed the risk. Collect the pregnancy outcome only; treatment timing is not relevant. Record the exposure as evidence of REMS failure without investigating the circumstances.

Question 4 of 10 Which statement best distinguishes the ZENBEXUS REMS from routine pharmacovigilance?

The REMS processes individual adverse-event reports, while pharmacovigilance certifies pharmacies. The two systems are interchangeable and need not share relevant information. The REMS applies controlled measures to reduce fetal exposure risk; pharmacovigilance evaluates safety information and residual risk. The REMS confirms clinical benefit, while pharmacovigilance evaluates only treatment effectiveness.

Question 5 of 10 Which description best distinguishes iberdomide’s molecular-glue mechanism from conventional target inhibition?

It blocks the catalytic activity of the proteasome so that intracellular proteins cannot be degraded. It alters cereblon’s substrate-recognition properties, promoting recruitment and degradation of selected proteins. It binds a cancer-cell receptor and prevents that receptor from interacting with its natural ligand. It directly inhibits Ikaros and Aiolos without involving cellular protein-degradation machinery.

Question 6 of 10 A case report says only that a patient was “taking iberdomide” when an event occurred. Which additional information is especially useful given the approved intermittent schedule?

Whether the patient had ever received any anti-myeloma treatment. The name of the hospital where the patient was treated, instead of exposure dates. Whether the event was considered serious by the reporter, without further exposure details. Treatment cycle, dose, interruptions or reductions, and timing of the event relative to exposure.

Question 7 of 10 A patient develops pulmonary embolism while receiving iberdomide combination therapy. Which case detail would best support clinically meaningful assessment of this risk?

Classifying the event only as a general cardiovascular complaint. Capturing the specific event, diagnostic evidence, timing, relevant risk factors, prophylaxis, treatment and outcome. Recording only whether the patient had previously received an immunomodulatory drug. Assuming the event is unrelated if the patient had a known risk factor for thrombosis.

Question 8 of 10 A reporting database shows an increase in the number of iberdomide-associated infections after broader commercial use. What is the most appropriate next interpretive step?

Conclude that the infection risk has increased because the raw case count is higher. Consider exposure estimates and changes in the treated population, and assess the cases clinically before concluding that risk has changed. Dismiss the pattern if infection was already known before approval. Compare the raw number directly with a clinical-trial count, regardless of exposure duration.

Question 9 of 10 Why should a case processor preserve whether a thromboembolic event was venous or arterial?

The distinction is needed only for determining whether the patient had myeloma progression. Both types are interchangeable for clinical interpretation and signal assessment. The categories have different clinical implications and may have different contributing factors. Arterial events should be excluded from the product’s safety assessment.

Question 10 of 10 Why does FDA accelerated approval make continued evidence generation particularly important for iberdomide?

The approval establishes that long-term clinical benefit has already been confirmed. Approval based on a surrogate endpoint reasonably likely to predict benefit is subject to post-approval confirmation of clinical benefit. The confirmatory trial replaces the need for post-marketing safety surveillance. Accelerated approval means the medicine cannot be used outside clinical trials.

QPPV.com

Iberdomide (Zenbexus): CELMoD Development, Accelerated Approval and Pharmacovigilance — Knowledge Assessment

Cookie Settings